415 related articles for article (PubMed ID: 18794711)
1. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
3. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
[TBL] [Abstract][Full Text] [Related]
4. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
5. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease.
Freeman HJ
Can J Gastroenterol; 2005 Oct; 19(10):603-6. PubMed ID: 16247522
[TBL] [Abstract][Full Text] [Related]
6. Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.
Card TR; Langan SM; Chu TP
Dig Dis Sci; 2016 Sep; 61(9):2619-26. PubMed ID: 27193564
[TBL] [Abstract][Full Text] [Related]
7. Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
States V; O'Brien S; Rai JP; Roberts HL; Paas M; Feagins K; Pierce EJ; Baumgartner RN; Galandiuk S
Dig Dis Sci; 2020 Sep; 65(9):2675-2685. PubMed ID: 31925675
[TBL] [Abstract][Full Text] [Related]
8. Peripheral arthritis in the course of inflammatory bowel diseases.
Yüksel I; Ataseven H; Başar O; Köklü S; Ertuğrul I; Ulker A; Dağlı U; Saşmaz N
Dig Dis Sci; 2011 Jan; 56(1):183-7. PubMed ID: 20458624
[TBL] [Abstract][Full Text] [Related]
9. Mucocutaneous manifestations in inflammatory bowel disease.
Yüksel I; Başar O; Ataseven H; Ertuğrul I; Arhan M; Ibiş M; Dağli U; Demirel BT; Ulker A; Seçilmiş S; Saşmaz N
Inflamm Bowel Dis; 2009 Apr; 15(4):546-50. PubMed ID: 19023896
[TBL] [Abstract][Full Text] [Related]
10. Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population.
Jo UH; Lee JY; Lee H; Kim DY; Kang S; Koh SJ; Park H
J Dermatol; 2021 Apr; 48(4):431-438. PubMed ID: 33608949
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
[TBL] [Abstract][Full Text] [Related]
12. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
[TBL] [Abstract][Full Text] [Related]
13. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.
Weizman A; Huang B; Berel D; Targan SR; Dubinsky M; Fleshner P; Ippoliti A; Kaur M; Panikkath D; Brant S; Oikonomou I; Duerr R; Rioux J; Silverberg M; Rotter JI; Vasiliauskas E; Haritunians T; Shih D; Li D; Melmed GY; McGovern DP
Inflamm Bowel Dis; 2014 Mar; 20(3):525-33. PubMed ID: 24487271
[TBL] [Abstract][Full Text] [Related]
14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
[TBL] [Abstract][Full Text] [Related]
16. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
[TBL] [Abstract][Full Text] [Related]
17. Disease-related and drug-induced skin manifestations in inflammatory bowel disease.
Hindryckx P; Novak G; Costanzo A; Danese S
Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):203-214. PubMed ID: 28095714
[TBL] [Abstract][Full Text] [Related]
18. Treatment of erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum in patients with IBD.
Tremaine WJ
Inflamm Bowel Dis; 1998 Feb; 4(1):68-9; discussion 73. PubMed ID: 9552230
[No Abstract] [Full Text] [Related]
19. How prevalent are extraintestinal manifestations at the initial diagnosis of IBD?
Isaacs KL
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S198-9. PubMed ID: 18816779
[No Abstract] [Full Text] [Related]
20. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
